LivaNova (LIVN) Free Cash Flow Growth (3y) (2019 - 2026)
LivaNova (LIVN) Free Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.91 Bn | 193.31 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 127.59 Bn | 124.11 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 73.24 Bn | 72.70 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 34.38 Bn | 32.44 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 33.96 Bn | 31.85 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.08 Bn | 22.60 Bn | 684.20 Mn | 9.23% |
| 10 | LivaNova | 4.29 Bn | 3.77 Bn | 273.67 Mn | 51.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.61% |
| Mar 31, 2026 | -28.62% |
| Dec 31, 2025 | 73.72% |
| Sep 30, 2025 | 28.07% |
| Jun 30, 2025 | 70.06% |
| Mar 31, 2025 | -13.85% |
| Dec 31, 2024 | 38.17% |
| Sep 30, 2024 | 16.67% |
| Jun 30, 2024 | 17.51% |
| Mar 31, 2024 | -31.73% |
| Dec 31, 2023 | 10.51% |
| Sep 30, 2023 | 92.54% |
| Jun 30, 2023 | 5.96% |
| Mar 31, 2023 | 28.34% |
| Dec 31, 2022 | 57.47% |
| Sep 30, 2022 | 33.11% |
| Jun 30, 2022 | 12.52% |
| Mar 31, 2022 | 95.49% |
| Dec 31, 2021 | 47.80% |
| Sep 30, 2021 | -19.22% |